SCHEMBL680214

SCHEMBL680214

CCOC(=O)c1c(CBr)n(C)n(-c2ccc(F)cc2)c1=O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 1/20 0.42
ALOX5 P09917 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
MEN1 O00255 3/20 0.40
POLB P06746 1/20 0.39
GRM6 O15303 1/20 0.39
PRKCZ Q05513 1/20 0.39
MAPT P10636 2/20 0.39
APP P05067 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1258186 0.90 KMT2A (0.46) KMT2ANPC1LMNARAB9AALOX5
SCHEMBL680328 0.85 KMT2A (0.50) KMT2ANPC1LMNARAB9AGABRA2
SCHEMBL681007 0.82 KMT2A (0.45) KMT2ALMNAMEN1MAPTKDM4E
SCHEMBL680883 0.81 KMT2A (0.42) KMT2ANPC1LMNARAB9AGABRA2
SCHEMBL679238 0.80 NPSR1 (0.46) KMT2ALMNARAB9AMEN1MAPT
SCHEMBL198265 0.74 TSHR (0.45) KMT2ALMNAMEN1MAPTKDM4E
SCHEMBL8113306 0.74 ALDH1A1 (0.42) KMT2AGABRA2GABRB2MEN1GRM6
SCHEMBL1259421 0.74 FPR2 (0.42) KMT2ALMNAMEN1KDM4EALDH1A1
SCHEMBL4325141 0.73 MEN1 (0.38) KMT2ALMNARAB9AMEN1MAPT
SCHEMBL28344280 0.73 KDM4E (0.47) KMT2ANPC1LMNARAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC KMT2A 1681/4885NPC1 2162/4885LMNA 4448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.